首页> 美国卫生研究院文献>British Journal of Cancer >Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

【2h】

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

机译：Nintedanib联合紫杉醇在早期HER-2阴性乳腺癌中的I期临床试验（CNIO-BR-01-2010 / GEICAM-2010-10研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer.

机译：简介：以前的小分子抗血管生成剂已经损害了乳腺癌的化疗剂量强度。我们提出了一种新型选择剂nintedanib和标准化疗在早期乳腺癌中的I期试验。

著录项

期刊名称 British Journal of Cancer
作者
M Quintela-Fandino; A Urruticoechea; J Guerra; M Gil; A Gonzalez-Martin; R Marquez; E Hernandez-Agudo; C Rodriguez-Martin; M Gil-Martin; R Bratos; M J Escudero; S Vlassak; F Hilberg; R Colomer;
展开▼
作者单位

展开▼
年(卷),期 2014(111),6
年度 2014
页码 1060–1064
总页数 5
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
breast cancer nintedanib neoadjuvant HER-2-negative phase I clinical trial;

机译：乳腺癌;nintedanib;新辅助药;HER-2-阴性;I期;临床试验;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study) [J] . M Quintela-Fandino, A Urruticoechea, J Guerra, British Journal of Cancer . 2014,第6期

机译：Nintedanib联合紫杉醇用于早期HER-2阴性乳腺癌的I期临床试验（CNIO-BR-01-2010 / GEICAM-2010-10研究）
3. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer [J] . LangI., InbarM.J., KahánZ., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2012,第17期

机译：一线贝伐单抗与卡培他滨或紫杉醇联合治疗HER-2阴性的局部复发或转移性乳腺癌的III期研究（CECOG的TURANDOT试验，CECOG的安全性）
4. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer [J] . Schott Anne F., Goldstein Lori J., Cristofanilli Massimo, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第18期

机译：相IB试验研究，以患有Hever-2阴性转移乳腺癌患者的每周紫杉醇评估remarixin
5. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
6. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
7. Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial a randomized comparative phase 3 study [O] . Toru Watanabe, Masaru Kuranami, Kenichi Inoue, -1

机译：淋巴结阳性乳腺癌患者中AC-紫杉烷与AC非方案紫杉醇与多西他赛的比较：美国国家乳腺癌外科辅助研究02试验的最终结果（一项随机比较的3期研究）
8. Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01) [O] . K. Sato 2003

机译：每周紫杉醇的多中心期II试验晚期或转移性乳腺癌：埼玉乳腺癌临床研究组（SBCCSG-01）

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

摘要

著录项

相似文献

相关主题

期刊订阅